Market news
Smart Beta ETF report for XBI
B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
Over six years, U.S. nominal GDP rose 63% while the 30-year Treasury fell 60%. Are investors positioned for a surge in stocks and yields?
XBI may have peaked after a 60% rally as tailwinds fade, equity supply hits cycle highs, and momentum rolls over. Click to read more about XBI's sell rating.
VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.
Smart Beta ETF report for XTN
Smart Beta ETF report for XRT
Smart Beta ETF report for XHB
Buy XBI? Get outlook for the SPDR S&P Biotech ETF—8%–14% return target, M&A tailwinds, key risks, and volatility factors.
State Street SPDR S&P Biotech ETF is hovering around a buy point after breaking out. The fund is one of the holdings in IBD Leaderboard.
XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years.
Motley Fool Press Release.
XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend.
XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite?
Smart Beta ETF report for XBI
Initiating Buy ratings on SPDR S&P Biotech ETF and iShares Biotechnology ETF for 2026–2027, favoring XBI over IBB for higher upside. Click to read more.
AI stocks have come under heavy selling pressure in the stock market, but biotechs are still catching a bid among institutional investors.
XBI saw gains while the major indexes showed a rotation out of the AI leaders.
Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.
One offers broad stability with lower costs and higher income, while the other chases biotech growth and has steeper volatility.
This is the newest page. Registered accounts read further back.